A Phase II Study of Radscopal Radiotherapy Combined with Immunotherapy as First-Line Treatment for Chemotherapy-Ineligible Patients with De Novo Metastatic Nasopharyngeal Carcinoma (RADIANCE) (ChiCTR) - Sep 16, 2026 - P2 | N=28 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P2 trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1
|